Caladrius Biosciences Inc. (NASDAQ: CLBS) is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. The company is developing a first-in-class cell therapy product that is based on the notion that the human body contains finely tuned mechanisms for self-repair. Caladrius Biosciences’ technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform. For more information, visit the company’s website at www.caladrius.com.
To register for The LD 500 and watch the live presentation, visit http://ibn.fm/TheLD500Registration
To view IBN’s virtual coverage of The LD 500, visit https://ibn.fm/TheLD500
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at The LD 500. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of next month’s The LD 500.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations in 2020, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]